This study revealed that when anti-IL-17 BAs were used to treat moderate to severe psoriasis, the incidence of TEAEs was 71.32%, whereas that of SAEs was 4.46% (Supplementary Figures 15, 16). Here, IL17A is linked to psoriasis.